Description
Ipamorelin/CJC-1295 Blend for Laboratory Research
Ipamorelin/CJC-1295 Blend is a synthetic peptide blend supplied for controlled laboratory investigation. This blend combines Ipamorelin, a selective growth hormone secretagogue, with CJC-1295, a modified growth hormone-releasing hormone (GHRH 1-29) analogue featuring a Drug Affinity Complex (DAC) for an extended half-life. Researchers study this compound to understand its effects on the somatotropic axis and the modulation of growth hormone secretion in various research models, enabling repeatable studies under standardized conditions.
Because of its defined composition and extended action profile, researchers value this blend for investigating sustained endocrine responses. The inclusion of DAC in CJC-1295 allows for the study of prolonged GHRH receptor activation, providing consistent data on signaling patterns and interaction behavior in controlled environments. This facilitates the examination of complex regulatory mechanisms within the growth hormone cascade, supporting precise and reproducible experimental outcomes.
In laboratory settings, Ipamorelin/CJC-1295 Blend is handled and prepared following standard peptide preparation and safety procedures. This product is supplied as a 10mg lyophilized powder in a sealed vial. For reconstitution, bacteriostatic water is typically employed. Once reconstituted, the solution should be stored under refrigerated conditions at 2-8°C and may be frozen at -20°C for extended storage to maintain its stability and integrity for subsequent experimental use.
The consistent composition of this blend ensures reduced variation across experimental batches, making it highly compatible with structured research workflows. Its suitability for long-term laboratory projects allows for the detailed investigation of sustained biological effects and dose-response characteristics. This compound provides a reliable tool for researchers seeking consistent data in their endocrine and metabolic studies.
Ongoing research continues to include Ipamorelin/CJC-1295 Blend due to its defined sequences and stable behavior in controlled research models. Its utility in examining the somatotropic axis makes it a valuable resource for advanced physiological studies.
Important Notice: Ipamorelin/CJC-1295 Blend 10mg is provided strictly for research use only. This product is not intended for human or animal use, clinical applications, diagnostic procedures, or consumption of any kind. All research must be conducted by qualified professionals in appropriate laboratory environments and in compliance with applicable regulations and guidelines.
Frequently Asked Questions
What is Ipamorelin/CJC-1295 Blend?
Ipamorelin/CJC-1295 Blend is a synthetic peptide combination consisting of Ipamorelin, a pentapeptide and selective growth hormone secretagogue, and CJC-1295 (CAS 863288-34-0), a 29-amino acid modified growth hormone-releasing hormone analogue (GHRH 1-29) with a Drug Affinity Complex (DAC). This blend is supplied for laboratory research to investigate the synergistic modulation of the growth hormone axis.
How does the DAC modification in CJC-1295 influence its research applications?
The Drug Affinity Complex (DAC) modification in CJC-1295 significantly extends its half-life in research models. This extension allows for sustained interaction with GHRH receptors, leading to a more prolonged and stable release of growth hormone from the pituitary gland. Researchers utilize this characteristic to study long-term physiological responses and stable pharmacokinetic profiles without the need for frequent administration in experimental protocols.
What biological systems are studied using Ipamorelin/CJC-1295 Blend?
Researchers primarily use Ipamorelin/CJC-1295 Blend to study the somatotropic axis and its components. This includes the pituitary gland, growth hormone secretagogue receptors (GHSRs), and growth hormone-releasing hormone (GHRH) receptors. Studies focus on understanding endocrine regulation, the dynamics of growth hormone release, and its downstream effects on various metabolic pathways in controlled laboratory settings.
What is the proposed mechanism of action for this blend in research models?
In research models, Ipamorelin acts as a selective agonist of the growth hormone secretagogue receptor (GHSR), stimulating growth hormone release without significantly impacting other pituitary hormones. CJC-1295, conversely, functions as an agonist of the GHRH receptor, promoting growth hormone secretion via a distinct pathway. The blend is studied for its potential to elicit a more robust and sustained growth hormone pulse through these complementary mechanisms.
Why is Ipamorelin/CJC-1295 Blend of interest in endocrine research?
Ipamorelin/CJC-1295 Blend is of interest in endocrine research due to its capacity for precise and sustained modulation of growth hormone secretion. It allows scientists to investigate complex regulatory loops within the somatotropic axis and understand how different receptor pathways contribute to overall growth hormone dynamics. This makes it a valuable tool for studying endocrine homeostasis, metabolic regulation, and potential age-related changes in growth hormone secretion patterns.
What are the recommended storage and reconstitution procedures for Ipamorelin/CJC-1295 Blend?
For optimal stability, Ipamorelin/CJC-1295 Blend should be stored as a lyophilized powder in a cool, dry environment away from direct light. Reconstitution is typically performed using sterile bacteriostatic water. After reconstitution, the solution should be refrigerated at 2-8°C for short-term use, and for extended storage, freezing at -20°C is recommended. Researchers must adhere to sterile techniques during handling to prevent degradation and contamination.
Reviews
There are no reviews yet.